ASCO Breast Cancer Updates - Living Beyond Breast Cancer · Progress in all Receptor Subtypes! ......

ASCO Breast Cancer Updates

Debu Tripathy, MD

Department of Breast Medical Oncology

The University of Texas MD Anderson Cancer Center, Houston, TX

Disclosures:

Research Support: Novartis, Pfizer, Polyphor

Honoraria for Steering Committee Service: GSK, Novartis, Pfizer

Consulting: Genomic Health

Progress in all Receptor Subtypes! – HR+, Triple Negative, HER+

• Improved Survival From CDK 4/6 Inhibitor Ribociclib

• Longer Time To Progression With AKT Inhibitor

• More Precise Decision-making For Adjuvant Chemotherapy

• Improved Survival From Immunotherapy – Checkpoint Inhibitor Atezolizumab

• Engineered HER2 Antibody Provides a Benefit Over Trastuzumab (Herceptin)

• Neratinib as a HER2 Kinase Inhibitor Partner With Capecitabine

• Longer Adjuvant Endocrine Therapy – When Does It Help?

Santarpia L et al. The Oncologist 2016

The Fluid State of the Tumor Micro-Ecosystem: Genomic Evolution and

Adaptive Resistance

MONALEESA-7 Study Design

Stratification Factors • Liver/lung metastasis (yes/no)• Prior chemotherapy (yes/no)• Combination partner (NSAI/TAM)

4

Primary endpoint • PFS (local)

Key secondary endpoint • OS

Select secondary endpoints • HRQOL• ORR• TTDD of ECOG PS• Safety

Pre/perimenopausal womena with

HR+/HER2− ABC

No prior ET for ABCb

≤ 1 prior CT for ABC

N = 672

Ribociclib 600 mg/day;

3 weeks on/1 week off +

NSAI/TAMc + GOSd

n = 335

Placebo 3 weeks on/1 week off

+ NSAI/TAMc + GOSd

n = 337

ANA, anastrozole; CT, chemotherapy; ECOG PS, Eastern Cooperative Oncology Group performance status; FSH, follicle-stimulating hormone; GOS, goserelin; HRQOL, health-related quality of life; NSAI, nonsteroidal aromatase inhibitor; ORR, objective response rate; TAM, tamoxifen; TTDD, time to definitive deterioration. a Premenopausal status was defined as either patient had last menstrual period ≤ 12 months or if receiving TAM or toremifene for ≤ 14 days, plasma estradiol and FSH must be in normal premenopausal range or in the case of induced amenorrhea, plasma estradiol and FSH must be in normal premenopausal range. Perimenopausal status was defined as neither premenopausal nor postmenopausal (prior bilateral oophorectomy, age ≥ 60 years, or FSH and plasma estradiol levels in normal postmenopausal range). Patients could not be ≥ 60 years of age. b Patients who received ≤ 14 days of NSAI/TAM ± GOS were allowed. c TAM and NSAI were administered daily orally. TAM dose was 20 mg, LET dose was 2.5 mg. and ANA dose was 1 mg. d GOS 3.6 mg was administered by subcutaneous injection.

First Phase III trial with a CDK4/6 inhibitor exclusively in premenopausal patients

Dr Sara Hurvitz

Ran

dom

ized

1:1

CDK4/6 Controls Cell Cycle Progression From G1 to S Phase by Regulating the Activity of Rb

E2F activates transcription of genes necessary for S-phase entry and

cell cycle progression2

Synthesis of D-type cyclins (cyclin D1, D2, and D3) and association with

CDK4/6 is initiated in response to mitogenic

signaling pathways1

Active cyclin D–CDK4/6 phosphorylates Rb, decoupling Rb from E2F and allowing

transcription of genes required for cell cycle progression1

Rb inhibits E2F-mediated transcription by binding to and

sequestering E2F2

1. Lange CA, et al. Endocr Relat Cancer. 2011 2. Rader J, et al. Clin Cancer Res 2013

Figure adapted from Lange CA, et al. Endocr Relat Cancer 2011

MONALEESA-7: Primary endpoint: PFS (investigator-assessed)

Pro

bab

ility

of

PFS

(%

)

Time (months) No. at risk Ribociclib + tamoxifen/NSAI 335 301 284 264 245 235 219 178 136 90 54 40 20 3 1 0

Placebo + tamoxifen/NSAI 337 273 248 230 207 183 165 124 94 62 31 24 13 3 1 0

PFS (investigator assessment)

Ribociclib + tamoxifen/NSAI n=335

Placebo + tamoxifen/NSAI n=337

Number of events, n (%) 131 (39.1) 187 (55.5)

Median PFS, months (95% CI)

23.8 (19.2–NR)

13.0 (11.0–16.4)

10 8 6 4 2 0

100

80

60

40

20

0

30 28 26 24 22 20 18 16 14 12

10

30

50

70

90

Hazard ratio (95% CI) 0.553 (0.441–0.694)

One-sided p value < 0.0001

Tripathy D, et al. Lancet Oncol 2018

Overall Survival

7 Dr Sara Hurvitz

Ribociclib + ET Placebo + ET Events/N 83/335 109/337

Median OS, mo Not reached 40.9

HR (95% CI) 0.712 (0.535-0.948) P value .00973

Kaplan-Meier Estimate Ribociclib + ET Placebo + ET

36 months 71.9% 64.9%

42 months 70.2% 46.0%

• ≈ 29% relative reduction in risk of death

• The P value of .00973 crossed the prespecified boundary to claim superior efficacy

Landmark Analysis

Overall Survival in the NSAI Subgroup

8 Dr Sara Hurvitz

Ribociclib + ET Placebo + ET Events/n 61/248 80/247

Median OS, mo Not reached 40.7

HR (95% CI) 0.699 (0.501-0.976)

Kaplan-Meier Estimate Ribociclib + ET Placebo + ET

36 months 72.2% 64.6%

42 months 69.7% 43.0%

Landmark Analysis

• ≈ 30% relative reduction in risk of death

Time to First Subsequent Chemotherapy

9 Dr Sara Hurvitz

Ribociclib + ET Placebo + ET

Events/n 95/335 139/337

Median time to CT, months Not reached 36.9

HR (95% CI) 0.596 (0.459-0.774)

Kaplan-Meier Estimate


36 months 67.2% 53.8%

42 months 65.8% 49.0%

Landmark Analysis

Progression-Free Survival 2

10 Dr Sara Hurvitz


Events/n 126/335 161/337

Median PFS2, mo Not reached 32.3

HR (95% CI) 0.692 (0.548-0.875)

Kaplan-Meier Estimate


36 months 58.4% 46.2%

42 months 54.6% 37.8%

PFS 2: time from randomization to

progression on the next line of therapy or

death

Landmark Analysis

San Antonio Breast Cancer Symposium, December 5–9, 2017

This presentation is the intellectual property of Debu Tripathy.

Contact [email protected] for permission to reprint and/or distribute.

Hematologic adverse events Regardless of study treatment relationship

AEs ≥5% in either arm, %

Ribociclib + tamoxifen/NSAI

n=335

Placebo + tamoxifen/NSAI

n=337

All Grade 3 Grade 4 All Grade 3 Grade 4

Neutropenia 75.8 50.7 9.9 7.7 3.0 0.6

Leukopenia 31.3 13.1 1.2 5.6 1.2 0

Anemia 20.9 3.0 0 10.1 2.1 0

Thrombocytopenia 8.7 0.6 0.3 2.1 0.3 0.3

• Febrile neutropenia occurred in 2.1% of patients in the ribociclib arm vs 0.6% of patients in the placebo arm

Tripathy D, et al. SABCS 2017

mailto:[email protected]

San Antonio Breast Cancer Symposium, December 5–9, 2017

This presentation is the intellectual property of Debu Tripathy.

Contact [email protected] for permission to reprint and/or distribute.

Non-hematologic adverse events Regardless of study treatment relationship

AEs ≥20% in either arm, %

Ribociclib + tamoxifen/NSAI

n=335

Placebo + tamoxifen/NSAI

n=337

All Grade 3 Grade 4 All Grade 3 Grade 4

Hot flush 34.0 0.3 0 33.5 0 0

Nausea 31.6 0.6 0 19.6 0.3 0

Arthralgia 29.9 0.9 0 27.3 0.9 0

Fatigue 23.6 1.2 0 24.6 0 0

Headache 23.0 0 0 24.3 0.9 0

Diarrhea 20.3 1.5 0 18.7 0.3 0

• Post-baseline QTcF >480 msec, based on ECG data, occurred in 23 patients (6.9%) in the ribociclib arm vs 4 patients (1.2%) in

the placebo arm

– Post-baseline QTcF >500 msec occurred in 5 patients (1.5%) vs 1 patient (0.3%)

• Treatment discontinuation due to QT prolongation AEs occurred in 1 patient (0.3%) in the ribociclib arm vs 2 patients (0.6%)

in the placebo arm

• QT prolongation events were not associated with clinical symptoms or arrhythmia

Tripathy D, et al. SABCS 2017

mailto:[email protected]

San Antonio Breast Cancer Symposium®, December 4-8, 2018

The Importance of the PI3K/AKT/mTOR Pathway in HR+ Breast Cancer

• The PI3K pathway is frequently altered in HR+

breast cancer and has been implicated in

resistance to endocrine therapies1,2

• Approximately 40% of HR+ breast cancers

harbor a PIK3CA mutation, leading to

hyperactivation of the PI3K pathway3-5

• PI3K signaling has been shown to promote

estrogen-independent growth of ER+ breast

cancer cells,6,7 and this growth is inhibited by

the addition of PI3K inhibitors to antiestrogens8 Figure reprinted by permission from Springer Nature: Nature Reviews Drug Discovery. Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery.

Hennessy BT, et al. Nat Rev Drug Discov. 2005 Dec;4(12):988-1004. © 2005.


Slide 2


PI3K/AKT/PTEN pathway in ER positive Breast Cancer


Capivasertib (AZD5363) in ER positive breast cancer


FAKTION Trial design


Progression Free Survival in the ITT population<br />


Progression Free Survival by PI3K/AKT/PTEN pathway activation status


Objective Response Rates in those with measurable disease


Overall survival


Notable adverse events affecting >10% of the study population


Conclusions


Slide 1


Background: Rationale for Integrating Genomic and Clinical Risk in Early Breast Cancer


TAILORx Results: Association between Continuous RS 11-25 and 9-Year Distant Recurrence Rate by Treatment Arms Stratified by Age (</=50 vs.>50 Years)<br />


Objectives and Methods: TAILORx Secondary Objective


Results: Impact of Clinical Risk (CR) on Prognosis by RS Group and Age


Results: Absolute Differences in 9-year Distant Recurrence Rate by Clinical Risk Stratified by Age, RS, and Chemotherapy Use


Slide 8


Slide 9


Conclusions: Integrating Clinical and Genomic Risk in Breast Cancer to Guide Adjuvant Therapy


Potential Clinical Utility of Integrated RS and Clinical Risk for Guiding Treatment in Women < 50 Years


IMpassion130: updated OS from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab + nab-paclitaxel in previously untreated locally advanced or metastatic TNBC


Background


IMpassion130 Study Design


Primary PFS Analysis in the ITT and PD-L1 IC+ Subgroup


OS in ITT Population


OS in PD-L1+ Population


Updated Safety Analysisa


Conclusions


Slide 1


Persistent Unmet Need in HER2+ MBC After Anti-HER2 Therapy


Margetuximab: Fc-engineered to Activate Immune Responses


Study CP-MGAH22-04 (SOPHIA) Design1,2


PFS Analysis in ITT Population


Planned Exploratory PFS Analysis by CD16A Genotype, by CBA


Conclusions


Neratinib plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with ≥2 HER2-directed regimens: Findings from the multinational, randomized, phase 3 NALA trial


Neratinib: An irreversible pan-HER TKI


Clinical experience with neratinib


NALA study design


Centrally confirmed PFS (co-primary endpoint)


Prespecified restricted means analysis – PFS


OS (co-primary endpoint)


Time to intervention for CNS metastases


Response rate and duration of response


Most frequent grade 3/4 adverse events


Conclusions


Benefit from letrozole as extended adjuvant therapy after sequential endocrine therapy: A randomized, phase III study of the Gruppo Italiano Mammella (GIM)


GIM4 Study Design


Treatment compliance


Slide 9


DFS first events by treatment

Presented By Lucia Del Mastro at 2019 ASCO Annual Meeting


Slide 14


Extended adjuvant AI studies

Presented By Lucia Del Mastro at 2019 ASCO Annual Meeting

ASCO Breast Cancer Updates - Living Beyond Breast Cancer · Progress in all Receptor Subtypes! ......

Documents

Transcript of ASCO Breast Cancer Updates - Living Beyond Breast Cancer · Progress in all Receptor Subtypes! ......